• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5081156)   Today's Articles (1159)
For: Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2020;382:1331-1342. [PMID: 32242358 PMCID: PMC7731441 DOI: 10.1056/nejmoa1914347] [Citation(s) in RCA: 1254] [Impact Index Per Article: 250.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Number Cited by Other Article(s)
1
Bi S, Shen J, Zhu Y, Fan L, Ju H, Liu Y. DNA scaffold-framed natural killer cell with programmed drug release for chemo-adoptive cell therapy. J Control Release 2025;382:113679. [PMID: 40180252 DOI: 10.1016/j.jconrel.2025.113679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2024] [Revised: 03/30/2025] [Accepted: 03/31/2025] [Indexed: 04/05/2025]
2
Markelov V, Arabuli KV, Gaponenko I, Sergeev V, Shakirova A, Lepik KV, Kulagin AD, Zyuzin MV. Scalable and ultrafast CAR-T cell production using microfluidics. LAB ON A CHIP 2025;25:3005-3015. [PMID: 40396473 DOI: 10.1039/d5lc00139k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2025]
3
Jain MD, Abramson JS, Ansell SM. Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies. Am Soc Clin Oncol Educ Book 2025;45:e473916. [PMID: 40294348 DOI: 10.1200/edbk-25-473916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2025]
4
Zhou L, Feng Y, Hong R, Wei G, Zhang M, Chang AH, Huang H, Hu Y. Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following chimeric antigen receptor T-cell therapy. SCIENCE CHINA. LIFE SCIENCES 2025;68:1703-1713. [PMID: 40189492 DOI: 10.1007/s11427-024-2783-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2024] [Accepted: 11/07/2024] [Indexed: 05/28/2025]
5
O'Shea PJ, Johnson PC, El-Jawahri A, Leblanc TW. Unmet needs and lived experience of patients receiving CAR T-cell therapy. Leuk Lymphoma 2025;66:1010-1020. [PMID: 39838695 DOI: 10.1080/10428194.2025.2455488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2024] [Revised: 12/16/2024] [Accepted: 01/14/2025] [Indexed: 01/23/2025]
6
Franco-Fuquen P, Figueroa-Aguirre J, Martínez DA, Moreno-Cortes EF, Garcia-Robledo JE, Vargas-Cely F, Castro-Martínez DA, Almaini M, Castro JE. Cellular therapies in rheumatic and musculoskeletal diseases. J Transl Autoimmun 2025;10:100264. [PMID: 39931050 PMCID: PMC11808717 DOI: 10.1016/j.jtauto.2024.100264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2024] [Revised: 12/12/2024] [Accepted: 12/13/2024] [Indexed: 02/13/2025]  Open
7
Liu WH, Globerson Levin A, Lask A, Horn G, Waks T, Nathansohn Levi B, Milman Krentsis I, Shoshan E, Su X, Mamonkin M, Champlin RE, Reisner Y, Bachar Lustig E. Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy. Stem Cells Transl Med 2025;14:szaf020. [PMID: 40448965 DOI: 10.1093/stcltm/szaf020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2024] [Accepted: 04/17/2025] [Indexed: 06/02/2025]  Open
8
Gu J, Li J, Xu Y, Zhang G, Xie J, Jia R, Chen W, Lu Z, Chang C, Wen H, Chang LJ, Ma H, Cai Q. Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas. J Transl Med 2025;23:591. [PMID: 40420236 DOI: 10.1186/s12967-025-06523-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2025] [Accepted: 04/21/2025] [Indexed: 05/28/2025]  Open
9
Pinto IS, Cordeiro RA, Oliveira ASR, Serra AC, Coelho JFJ, Faneca H. Polymer-Based DNA Delivery Nanoplatforms for Chimeric Antigen Receptor T Cells Engineering. Biomacromolecules 2025. [PMID: 40421765 DOI: 10.1021/acs.biomac.5c00208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2025]
10
Kaestner V, Haslam A, Prasad V. Characterization of bridging therapies in clinical trials leading to FDA approval of CAR-T cell therapies. Int J Cancer 2025. [PMID: 40394455 DOI: 10.1002/ijc.35473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2024] [Revised: 03/04/2025] [Accepted: 04/24/2025] [Indexed: 05/22/2025]
11
Long AH, Aftandilian C, Barmettler S, Alexander S. Hypogammaglobulinemia in Children Receiving Targeted Immunotherapies for B Lineage Malignancies: Practical Guidance for Assessment and Management. Pediatr Blood Cancer 2025:e31779. [PMID: 40372257 DOI: 10.1002/pbc.31779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/11/2025] [Revised: 04/21/2025] [Accepted: 04/24/2025] [Indexed: 05/16/2025]
12
Song KW, Lim M, Monje M. Complex neural-immune interactions shape glioma immunotherapy. Immunity 2025;58:1140-1160. [PMID: 40324379 DOI: 10.1016/j.immuni.2025.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2025] [Revised: 04/14/2025] [Accepted: 04/15/2025] [Indexed: 05/07/2025]
13
Zang SS, Zhang R, Zhang JR, Zhang X, Li J. Progress, Applications and Prospects of CRISPR-Based Genome Editing Technology in Gene Therapy for Cancer and Sickle Cell Disease. Hum Gene Ther 2025. [PMID: 40351170 DOI: 10.1089/hum.2024.262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2025]  Open
14
Zhang Z, Zheng J, Liang Y, Wu Q, Ding C, Ma L, Su L. Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. BMC Cancer 2025;25:846. [PMID: 40346502 PMCID: PMC12063233 DOI: 10.1186/s12885-025-14227-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2024] [Accepted: 04/25/2025] [Indexed: 05/11/2025]  Open
15
Huang Y, Gong Y, Liu X, Ruan H, Lu J, Kouros-Mehr H, Liu H, Wang H. Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma. Front Immunol 2025;16:1567149. [PMID: 40406106 PMCID: PMC12096171 DOI: 10.3389/fimmu.2025.1567149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2025] [Accepted: 04/14/2025] [Indexed: 05/26/2025]  Open
16
Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. N Engl J Med 2025;392:1824-1835. [PMID: 40334157 DOI: 10.1056/nejmoa2408771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/09/2025]
17
Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: The evolution of CAR-T cell therapy. Mol Ther 2025;33:2123-2140. [PMID: 40070120 DOI: 10.1016/j.ymthe.2025.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2025] [Revised: 03/04/2025] [Accepted: 03/05/2025] [Indexed: 03/21/2025]  Open
18
Liebers N, Boumendil A, Finel H, Edelmann D, Kobbe G, Baermann BN, Serroukh Y, Blaise D, Beelen DW, Solano C, Itälä-Remes M, van Meerten T, Choi G, Schmidt SAC, Kröger N, Byrne J, Tudesq JJ, Ossami Saidy A, Nunes A, Siddiqi R, Baro E, Zheng D, Kloos I, Dreger P, Sureda A, Glass B, Dietrich S. Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma. Blood Cancer Discov 2025;6:182-190. [PMID: 39913291 PMCID: PMC12050943 DOI: 10.1158/2643-3230.bcd-24-0178] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2024] [Revised: 10/27/2024] [Accepted: 02/04/2025] [Indexed: 05/06/2025]  Open
19
Ouyang Z, Zeng R, Wang S, Wu X, Li Y, He Y, Wang C, Xia C, Ou Q, Bao H, Yang W, Xiao L, Zhou H. Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma. Cancer Cell Int 2025;25:172. [PMID: 40319323 PMCID: PMC12049778 DOI: 10.1186/s12935-025-03789-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2025] [Accepted: 04/12/2025] [Indexed: 05/07/2025]  Open
20
Yan S, Zhou M, Zhu X, Xiao Y. Neurological complications associated with chimeric antigen receptor T cell therapy. J Cereb Blood Flow Metab 2025:271678X251332492. [PMID: 40314208 PMCID: PMC12048402 DOI: 10.1177/0271678x251332492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2024] [Revised: 02/20/2025] [Accepted: 03/14/2025] [Indexed: 05/03/2025]
21
Mamo T, Meulners L, Johnson A, Thibodeaux S, McKenna D. Apheresis collection parameters for approved CAR T-cell products need to be standardized. Transfusion 2025;65:1021-1025. [PMID: 40191912 DOI: 10.1111/trf.18216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2025] [Revised: 03/06/2025] [Accepted: 03/10/2025] [Indexed: 05/21/2025]
22
Wang J, Chen Q, Shan Q, Liang T, Forde P, Zheng L. Clinical development of immuno-oncology therapeutics. Cancer Lett 2025;617:217616. [PMID: 40054657 PMCID: PMC11930610 DOI: 10.1016/j.canlet.2025.217616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2024] [Revised: 03/03/2025] [Accepted: 03/05/2025] [Indexed: 03/15/2025]
23
Weiss JM, Phillips TJ. SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2025;25:304-308. [PMID: 39523133 DOI: 10.1016/j.clml.2024.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/04/2024] [Accepted: 10/10/2024] [Indexed: 11/16/2024]
24
Canelo-Vilaseca M, Sabbah M, Di Blasi R, Cristinelli C, Sureda A, Caillat-Zucman S, Thieblemont C. Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma. Bone Marrow Transplant 2025;60:559-567. [PMID: 40148484 PMCID: PMC12061774 DOI: 10.1038/s41409-025-02539-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2024] [Revised: 09/29/2024] [Accepted: 02/17/2025] [Indexed: 03/29/2025]
25
Mulvey A, Trueb L, Coukos G, Arber C. Novel strategies to manage CAR-T cell toxicity. Nat Rev Drug Discov 2025;24:379-397. [PMID: 39901030 DOI: 10.1038/s41573-024-01100-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2024] [Indexed: 02/05/2025]
26
Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, Gergis U, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez JC. Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. Bone Marrow Transplant 2025;60:632-639. [PMID: 40025178 DOI: 10.1038/s41409-025-02541-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2024] [Revised: 01/12/2025] [Accepted: 02/19/2025] [Indexed: 03/04/2025]
27
Azmal M, Miah MM, Prima FS, Paul JK, Haque ASNB, Ghosh A. Advances and challenges in cancer immunotherapy: Strategies for personalized treatment. Semin Oncol 2025;52:152345. [PMID: 40305928 DOI: 10.1016/j.seminoncol.2025.152345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2024] [Revised: 03/11/2025] [Accepted: 03/17/2025] [Indexed: 05/02/2025]
28
Sonar PV, Singh AK, Mandadi S, Sharma NK. Expanding horizons of cancer immunotherapy: hopes and hurdles. Front Oncol 2025;15:1511560. [PMID: 40352591 PMCID: PMC12061710 DOI: 10.3389/fonc.2025.1511560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2024] [Accepted: 03/31/2025] [Indexed: 05/14/2025]  Open
29
Gazeau N, Beauvais D, Tilmont R, Srour M, Ferrant E, Safar V, Fouillet L, Flandrin-Gresta P, Gower N, Chauvet P, Duployez N, Podvin B, Demaret J, Huet S, Sujobert P, Ghesquières H, Damaj G, Bachy E, Morschhauser F, Yakoub-Agha I, Heiblig M, Sesques P. Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time? Leukemia 2025:10.1038/s41375-025-02605-7. [PMID: 40275069 DOI: 10.1038/s41375-025-02605-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2025] [Revised: 03/09/2025] [Accepted: 04/02/2025] [Indexed: 04/26/2025]
30
Esmaeilzadeh A, Hadiloo K, Yaghoubi S, Makoui MH, Mostanadi P. State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment. Cell Oncol (Dordr) 2025:10.1007/s13402-025-01056-7. [PMID: 40261561 DOI: 10.1007/s13402-025-01056-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2025] [Accepted: 03/19/2025] [Indexed: 04/24/2025]  Open
31
Reidy M, Khan M, Mills EA, Wu Q, Garton J, Draayer DE, Zahoor I, Giri S, Axtell RC, Mao-Draayer Y. New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies. Int J Mol Sci 2025;26:3880. [PMID: 40332536 PMCID: PMC12028294 DOI: 10.3390/ijms26083880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2025] [Revised: 04/13/2025] [Accepted: 04/14/2025] [Indexed: 05/08/2025]  Open
32
Majhail NS, Cox T, Larson S, Battiwalla M, Ramakrishnan A, Shaughnessy P, Tees M, Zahradka N, Wilkes M, Pantin J. Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring. JCO Oncol Pract 2025:OP2500062. [PMID: 40249898 DOI: 10.1200/op-25-00062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2025] [Revised: 03/02/2025] [Accepted: 03/13/2025] [Indexed: 04/20/2025]  Open
33
Phanthaphol N, Somboonpatarakun C, Suwanchiwasiri K, Yuti P, Sujjitjoon J, Augsornworawat P, Baillie GS, Junking M, Yenchitsomanus PT. Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor T cells targeting integrin αvβ6 and secreting anti-PD-L1 scFv. J Transl Med 2025;23:451. [PMID: 40241132 PMCID: PMC12004729 DOI: 10.1186/s12967-025-06453-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2024] [Accepted: 04/02/2025] [Indexed: 04/18/2025]  Open
34
Dreger P, Ahmed S, Bazarbachi A, Dietrich S, Fenske TS, Ghosh N, Hermine O, Hamadani M. How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives. Bone Marrow Transplant 2025:10.1038/s41409-025-02599-x. [PMID: 40229536 DOI: 10.1038/s41409-025-02599-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2025] [Revised: 04/01/2025] [Accepted: 04/08/2025] [Indexed: 04/16/2025]
35
Zhao L, Yan F, Tang D, Li W, An N, Ren C, Wang Y, Xu K, Zhao K. The transition between M1 and M2 macrophage phenotypes is associated with the disease status following CD19 CAR-T therapy for B cell lymphoma/leukemia. Cell Death Dis 2025;16:275. [PMID: 40216772 PMCID: PMC11992075 DOI: 10.1038/s41419-025-07610-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2024] [Revised: 03/19/2025] [Accepted: 03/31/2025] [Indexed: 04/14/2025]
36
Lee MJ, Cichocki F, Miller JS. Chimeric antigen receptor therapies: Development, design, and implementation. J Allergy Clin Immunol 2025:S0091-6749(25)00386-0. [PMID: 40220909 DOI: 10.1016/j.jaci.2025.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2024] [Revised: 03/06/2025] [Accepted: 04/03/2025] [Indexed: 04/14/2025]
37
Stewart CM, Siegler EL, Kenderian SS. The road ahead for chimeric antigen receptor T cells. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2025:vkaf047. [PMID: 40209174 DOI: 10.1093/jimmun/vkaf047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/02/2025] [Accepted: 02/25/2025] [Indexed: 04/12/2025]
38
Roex G, Gordon KS, Lion E, Birnbaum ME, Anguille S. Expanding the CAR toolbox with high throughput screening strategies for CAR domain exploration: a comprehensive review. J Immunother Cancer 2025;13:e010658. [PMID: 40210240 PMCID: PMC11987143 DOI: 10.1136/jitc-2024-010658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2024] [Accepted: 03/06/2025] [Indexed: 04/12/2025]  Open
39
Shahid S, Prockop SE, Flynn GC, Mauguen A, White CO, Bieler J, McAvoy D, Hosszu K, Cancio MI, Jakubowski AA, Scaradavou A, Boelens JJ, Sauter CS, Perales MA, Giralt SA, Taylor C, Chaudhari J, Wang X, Rivière I, Sadelain M, Brentjens RJ, Kernan NA, O'Reilly RJ, Curran KJ. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies. Blood Adv 2025;9:1644-1657. [PMID: 39908482 PMCID: PMC11995077 DOI: 10.1182/bloodadvances.2024015157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2024] [Revised: 12/10/2024] [Accepted: 12/31/2024] [Indexed: 02/07/2025]  Open
40
Morgan HT, Derman BA, Ma H, Kumar SK. Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias. Front Immunol 2025;16:1558275. [PMID: 40264764 PMCID: PMC12011880 DOI: 10.3389/fimmu.2025.1558275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2025] [Accepted: 03/10/2025] [Indexed: 04/24/2025]  Open
41
Yu W, Li P, Zhou L, Yang M, Ye S, Zhu D, Huang J, Yao X, Zhang Y, Li L, Zhao J, Zhu K, Li J, Zheng C, Lan L, Wan H, Yao Y, Zhang H, Zhou D, Jin J, Liang A. A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 2025;145:1526-1535. [PMID: 39813680 DOI: 10.1182/blood.2024026401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2024] [Revised: 12/09/2024] [Accepted: 12/09/2024] [Indexed: 01/18/2025]  Open
42
Bindal P, Trottier CA, Elavalakanar P, Dodge LE, Kim S, Logan E, Ma S, Liegel J, Arnason J, Alonso CD. Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy. Leuk Lymphoma 2025;66:702-712. [PMID: 39704413 DOI: 10.1080/10428194.2024.2439513] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2024] [Revised: 10/28/2024] [Accepted: 12/03/2024] [Indexed: 12/21/2024]
43
Marshalek JP, Qing X, Tomassetti S. CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy. World J Oncol 2025;16:235-238. [PMID: 40162108 PMCID: PMC11954608 DOI: 10.14740/wjon2534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2025] [Accepted: 02/12/2025] [Indexed: 04/02/2025]  Open
44
Mousavi S, Khazaee-Nasirabadi MH, Seyedmehdi MS, Bazi A, Mirzaee Khalilabadi R. Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in hematological malignancies. Leuk Lymphoma 2025;66:594-616. [PMID: 39656564 DOI: 10.1080/10428194.2024.2438802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Revised: 11/18/2024] [Accepted: 12/01/2024] [Indexed: 12/17/2024]
45
Wang Y, Ding L, Wang Y, Li H, Wu M, Li S, Xu Q, Chen Y, Wang X. Tetrandrine alleviates macrophage activation syndrome after CAR-T cell therapy. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2025;139:156483. [PMID: 39947004 DOI: 10.1016/j.phymed.2025.156483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/22/2024] [Revised: 01/22/2025] [Accepted: 02/06/2025] [Indexed: 05/09/2025]
46
Lalu MM, Igweokpala S, Kekre N, Jeffers MS, Montroy J, Ghiasi M, Hay K, McComb S, Weeratna R, Atkins H, Hutton B, Yahya A, Masurekar A, Giguere P, Sabri E, Sobh M, Fergusson DA. Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis. Transfus Med Rev 2025;39:150897. [PMID: 40280037 DOI: 10.1016/j.tmrv.2025.150897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2024] [Revised: 03/26/2025] [Accepted: 04/01/2025] [Indexed: 04/29/2025]
47
Graham CE, Velasco R, Alarcon Tomas A, Stewart OP, Dachy G, Del Bufalo F, Doglio M, Henter JI, Ortí G, Peric Z, Roddie C, van de Donk NWCJ, Frigault MJ, Ruggeri A, Onida F, Sánchez-Ortega I, Yakoub-Agha I, Penack O. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol 2025;26:e203-e213. [PMID: 40179916 DOI: 10.1016/s1470-2045(24)00715-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2024] [Revised: 12/03/2024] [Accepted: 12/04/2024] [Indexed: 04/05/2025]
48
Raj SS, Fei T, Fried S, Ip A, Fein JA, Leslie LA, Alarcon Tomas A, Leithner D, Peled JU, Corona M, Dahi PB, Danylesko I, Epstein-Peterson Z, Funnell T, Giralt SA, Jacoby E, Kedmi M, Landego I, Lin RJ, Parascondola A, Pascual L, Orozco N, Park JH, Palomba ML, Salles G, Saldia A, Schöder H, Sdayoor I, Shah GL, Scordo M, Shem-Tov N, Shimoni A, Slingerland J, Yerushalmi R, Nagler A, Greenbaum BD, Vickers AJ, Suh HC, Avigdor A, Perales MA, van den Brink MRM, Shouval R. An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma. Nat Med 2025;31:1183-1194. [PMID: 40169864 PMCID: PMC12003198 DOI: 10.1038/s41591-025-03532-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Accepted: 01/23/2025] [Indexed: 04/03/2025]
49
Zhang Q, Dai J, Liu T, Rao W, Li D, Gu Z, Huang L, Wang J, Hou X. Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells. Mol Cell Biochem 2025;480:2103-2116. [PMID: 39460827 DOI: 10.1007/s11010-024-05134-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2024] [Accepted: 10/04/2024] [Indexed: 10/28/2024]
50
Yang P, Li CY, Liu SZ, Wang J, Chen YT, Zhang WL, Jing HM. Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma. Ann Hematol 2025;104:2361-2371. [PMID: 40278919 PMCID: PMC12052948 DOI: 10.1007/s00277-025-06379-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2024] [Accepted: 04/18/2025] [Indexed: 04/26/2025]
PrevPage 1 of 26 123452526Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel